Effect of Pancreatic Kininogenase on Ventriculer Remodeling in Spontaneously Hypertensive Rats
Fu Ju
Abstract
Fu Ju
Abstract
Objective To investigate the effect of pancreatic kininogenase on the expression of matrix metalloproteinases-2 2(MMP-2), transfer growth factor-β_ 1 (TGF-β_ 1 ) and ventriculer remodeling in spontaneously hypertensive rats (SHR). Methods Twenty-four male 15 weeks SHR were randomly divided into three groups: SHR group, pancreatic kininogenase treatment group(PK: 7.2 U/kg·d), captopril treatment group(Cap: 10 mg/kg·d)(n=8 in each), 8 Wister Kyoto were served as control. After four weeks, blood pressure were measured througth carotid artery catherization. Myocardial tissue was stained with VG and pathological changes were studied. MMP-2, TGF-β_ 1 were determined by immunohisto-chemical technique(SP method). Results In pancreatic kininogenase treated SHR, SBP(183±12 vs SHR: 234±23)mm Hg, LVMI(2.89±0.15 vs SHR: 3.06±0.18)mg/g, CVF(0.17±0.03 vs SHR: 0.26±0.05)%, PVCA(0.57±0.26 vs SHR: 0.99±0.47)% and expression of MMP-2, TGF-β_ 1 in SHR were significantly improved (P0.05). All indexs were significantly decresed, and were close to captopril group. Conclusion Pancreatic kinigenase significantly reversed LVMI, CVF and PVCA, which may be mediated by attenuating expression of MMP-2 and TGF-β_1 in myocardial tissue.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Objective To investigate the effect of pancreatic kininogenase on the expression of matrix metalloproteinases-2 2(MMP-2), transfer growth factor-β_ 1 (TGF-β_ 1 ) and ventriculer remodeling in spontaneously hypertensive rats (SHR). Methods Twenty-four male 15 weeks SHR were randomly divided into three groups: SHR group, pancreatic kininogenase treatment group(PK: 7.2 U/kg·d), captopril treatment group(Cap: 10 mg/kg·d)(n=8 in each), 8 Wister Kyoto were served as control. After four weeks, blood pressure were measured througth carotid artery catherization. Myocardial tissue was stained with VG and pathological changes were studied. MMP-2, TGF-β_ 1 were determined by immunohisto-chemical technique(SP method). Results In pancreatic kininogenase treated SHR, SBP(183±12 vs SHR: 234±23)mm Hg, LVMI(2.89±0.15 vs SHR: 3.06±0.18)mg/g, CVF(0.17±0.03 vs SHR: 0.26±0.05)%, PVCA(0.57±0.26 vs SHR: 0.99±0.47)% and expression of MMP-2, TGF-β_ 1 in SHR were significantly improved (P0.05). All indexs were significantly decresed, and were close to captopril group. Conclusion Pancreatic kinigenase significantly reversed LVMI, CVF and PVCA, which may be mediated by attenuating expression of MMP-2 and TGF-β_1 in myocardial tissue.
Key concepts: Captopril, Internal medicine, Endocrinology, Matrix metalloproteinase, Medicine, Blood pressure, Pathological, Transforming growth factor